Castration-resistant prostate cancer: from new pathophysiology to new treatment. - Wikidata - awgldk - TriplyDB

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

http://www.wikidata.org/entity/Q38129971

about

Sipuleucel-T for metastatic castration-resistant prostate cancer Sipuleucel-T for metastatic castration-resistant prostate cancer Targeting the adaptive molecular landscape of castration-resistant prostate cancer Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer Dural metastases in advanced prostate cancer: a case report and review of the literature.Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer.Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy.Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer.Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.Cancer genetics: the origin and evolution of an ancient cancer.Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.PARP inhibition in castration-resistant prostate cancer.Oxibendazole inhibits prostate cancer cell growth.Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.

P2860

Q24186731-D253CF3E-9260-4B07-88B6-A22FD2B021FA Q26471816-02056CB8-BEC1-4824-9709-36045CFED2D4 Q27022821-0D1873B5-481A-4EAA-8D3C-F2CCF265114C Q30244818-FE6EE8B6-0D98-4FD2-B167-6BDD0C95B58A Q30878925-2CB0BB66-E442-4279-AA2D-595FBB3405CD Q31108842-6C11A7D9-3922-46BF-B3EE-BC55621C663F Q33702987-8DCCDCA1-EAA7-4176-9E6E-66C1C56719CD Q33718420-2B482980-DCC5-4830-8939-F0CE18A60D22 Q33775723-13F859CC-9ABA-4BA3-8799-8236371B9239 Q34052057-FEAF567A-56F7-4DAC-A8D1-08175B12390B Q35822185-E7F29208-F2CE-42BC-9E43-2E294C2C28E5 Q36167019-69DD21E7-EAD1-42EE-8CC9-B2E11081F38B Q36480632-35A54C27-385F-4EB3-917E-3BC482887975 Q37046523-F10F78B5-38F7-4C66-8722-1161910D0424 Q38219399-05D95349-DC11-4486-B4E7-2C2B6BC9E37B Q38769219-99D24AA4-6B9A-4669-A552-2AE1E7AE9D89 Q38818338-335E50F2-DCA9-4049-92D0-21345FA3390A Q38824206-703A627B-3EC9-46C3-826E-49393BD7DF79 Q38827251-34A2E8D2-2ECF-471E-829E-A39D160C47EB Q38838867-5249E161-E757-45DA-8046-84912429C15A Q38844202-254DFCB1-D01A-49CC-BC86-E55FE5DC2BA7 Q38895320-9C2F0AEB-57E6-42E5-B354-31D30173D72F Q38937417-800E2C88-1698-41C3-9FFA-36E14DF8074D Q40967736-7E72ED79-CF3B-4DBF-A22F-D3DB8FBCD179 Q41491922-CBD0306A-5373-4C88-A385-505F59FB5936 Q41709181-E13F1393-842F-4B25-9442-B892C2B749D3 Q44964713-A45D8C77-5BAC-4ECE-9148-DD294B2F90E2 Q47097189-C0A8CA67-8D69-4D98-955A-AC0CCBD6EC52 Q47399411-F5DE5A0F-08BD-4925-B997-3D4BEBEFFDA0 Q47435335-9A12AE9F-89F9-4759-B258-A5FACAEE90BB Q47670490-C327538F-9487-4CA5-BB56-2CD3AC338825 Q47703463-72C198FB-412C-46D7-88A4-5B1E3E4BE321 Q48139886-C5638966-11E4-4CBA-9415-AE9951797737 Q48193099-9B1B9A53-2115-4002-808B-F7A526C5391F Q48246094-29F0CA05-6F29-4DC9-922B-9F68F1544878 Q49530055-84008E99-EDA7-487E-8BEF-4A96C5F7E4F4 Q50074169-F761A454-507F-4D69-9A51-C93BE5FAEF19 Q52674354-67C85E3A-65C0-4933-B37D-6577D005727B Q53787362-3331B373-12A4-4162-B59F-FBD9465EC173 Q53822455-8A86E3EC-2F7B-412E-8AB0-D7147D651046

P2860

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

http://www.wikidata.org/entity/Q38129971

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

@en

type

label

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

@en

prefLabel

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

@en

P1433

Q38129971-51B3619D-D59B-423F-B0EF-2E626815C3E8

P1476

Q38129971-0395E7D4-05D5-4E6A-A698-49B478A80FF8

P2093

Q38129971-20F90C1E-FC45-4C78-A6F6-F81DFC2C75A1

Q38129971-27AC7C36-BA3B-4BE4-B654-285170ED834B

Q38129971-55B8C3BA-0A50-434A-81CA-ED7B7A9395C2

Q38129971-6955A922-9270-4F51-B5F3-27CB4E9C5292

Q38129971-9F385267-7974-4BD9-A489-841796522D30

Q38129971-CBDEB7B3-5135-467A-9115-6AFE77C4EC00

Q38129971-D8428024-B310-4103-956D-937A6C60D086

Q38129971-F564FA4B-653A-4271-A40E-16612F9DDA5E

P304

Q38129971-FDE60CC3-2E59-48B7-A7B6-CADC553DDD56

P31

Q38129971-9638FEC9-7075-47D4-9353-AB7C6F6B543F

P356

Q38129971-F8ADD9B3-19B5-462B-9609-7553C2B00635

P407

Q38129971-31B12C87-FDB0-4DFE-8011-5ED4C6F83ED2

P433

Q38129971-761FC493-150A-4665-AB8B-0FDEF4FB3DCA

P478

Q38129971-E336396D-06FD-4791-B6CF-E6D8D61E0256

P577

Q38129971-653D2FEB-809B-4F5E-B41F-35F583AFA647

P698

Q38129971-DD70478C-4DD1-4F2B-8BBC-47F14EEAEA52

P921

Q38129971-486F4A33-CA72-48BC-8844-B210FA0357DB

P356

J.EURURO.2013.08.008

P1433

European Urology

P1476

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

@en

P2093

Celestia Higano

http://www.w3.org/2001/XMLSchema#string

Chris Parker

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Martin E Gleave

http://www.w3.org/2001/XMLSchema#string

Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Peter Mulders

http://www.w3.org/2001/XMLSchema#string

Srikala S Sridhar

http://www.w3.org/2001/XMLSchema#string

Stephen J Freedland

http://www.w3.org/2001/XMLSchema#string

P304

289-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.08.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23957948

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology